Predicting cancer drug response by proteomic profiling
- PMID: 16899605
- DOI: 10.1158/1078-0432.CCR-06-0290
Predicting cancer drug response by proteomic profiling
Abstract
Purpose: Accurate prediction of an individual patient's drug response is an important prerequisite of personalized medicine. Recent pharmacogenomics research in chemosensitivity prediction has studied the gene-drug correlation based on transcriptional profiling. However, proteomic profiling will more directly solve the current functional and pharmacologic problems. We sought to determine whether proteomic signatures of untreated cells were sufficient for the prediction of drug response.
Experimental design: In this study, a machine learning model system was developed to classify cell line chemosensitivity exclusively based on proteomic profiling. Using reverse-phase protein lysate microarrays, protein expression levels were measured by 52 antibodies in a panel of 60 human cancer cell (NCI-60) lines. The model system combined several well-known algorithms, including random forests, Relief, and the nearest neighbor methods, to construct the protein expression--based chemosensitivity classifiers. The classifiers were designed to be independent of the tissue origin of the cells.
Results: A total of 118 classifiers of the complete range of drug responses (sensitive, intermediate, and resistant) were generated for the evaluated anticancer drugs, one for each agent. The accuracy of chemosensitivity prediction of all the evaluated 118 agents was significantly higher (P < 0.02) than that of random prediction. Furthermore, our study found that the proteomic determinants for chemosensitivity of 5-fluorouracil were also potential diagnostic markers of colon cancer.
Conclusions: The results showed that it was feasible to accurately predict chemosensitivity by proteomic approaches. This study provides a basis for the prediction of drug response based on protein markers in the untreated tumors.
Similar articles
-
An integrative genomic and proteomic approach to chemosensitivity prediction.Int J Oncol. 2009 Jan;34(1):107-15. doi: 10.3892/ijo_00000134. Int J Oncol. 2009. PMID: 19082483 Free PMC article.
-
In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.Genomics. 2009 Jan;93(1):52-61. doi: 10.1016/j.ygeno.2008.08.002. Epub 2008 Oct 22. Genomics. 2009. PMID: 18804159
-
Recent advances in clinical oncoproteomics.J BUON. 2007 Sep;12 Suppl 1:S31-8. J BUON. 2007. PMID: 17935275 Review.
-
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.Oncogene. 2005 Nov 17;24(51):7542-51. doi: 10.1038/sj.onc.1208908. Oncogene. 2005. PMID: 16044152
-
Predicting drug response based on gene expression.Crit Rev Oncol Hematol. 2004 Sep;51(3):205-27. doi: 10.1016/j.critrevonc.2004.06.002. Crit Rev Oncol Hematol. 2004. PMID: 15331079 Review.
Cited by
-
Distributionally robust learning-to-rank under the Wasserstein metric.PLoS One. 2023 Mar 30;18(3):e0283574. doi: 10.1371/journal.pone.0283574. eCollection 2023. PLoS One. 2023. PMID: 36996130 Free PMC article.
-
Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets.Cells. 2022 Dec 26;12(1):101. doi: 10.3390/cells12010101. Cells. 2022. PMID: 36611894 Free PMC article. Review.
-
Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma.Comput Struct Biotechnol J. 2022 Jul 2;20:3449-3460. doi: 10.1016/j.csbj.2022.06.064. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 35832634 Free PMC article.
-
Non-linearity of Metabolic Pathways Critically Influences the Choice of Machine Learning Model.Front Artif Intell. 2022 Jun 10;5:744755. doi: 10.3389/frai.2022.744755. eCollection 2022. Front Artif Intell. 2022. PMID: 35757298 Free PMC article.
-
Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer.Curr Oncol. 2022 Mar 7;29(3):1773-1795. doi: 10.3390/curroncol29030146. Curr Oncol. 2022. PMID: 35323346 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources